Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Altman

Showing results (341-350 of 365) with videos related to

Pageof 37
Sort By:
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2018
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJerald P Radich, Michael Deininger, Camille N Abboud, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Blood|December 5, 2018
Molecular remission and response patterns in patients with mutant-<i>IDH2</i> acute myeloid leukemia treated with enasidenibEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017Arnel Pallera, Jessica K Altman, Ellin Berman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2023
CML and the WHO: Why?Ellin Berman, Neil P Shah, Michael Deninger, et al.
Blood|October 16, 2025
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical TrialsAndrew Hantel, Yating Wang, Angel Cronin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P Shah, Ravi Bhatia, Jessica K Altman, et al.
Cancer|December 3, 2020
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a studyGautam Borthakur, Yishai Ofran, Martin S Tallman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I TrialNaseema Gangat, Christian Marinaccio, Ronan Swords, et al.
Pageof 37

Showing results (341-350 of 365) with videos related to

Sort By:
Pageof 37
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2018
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJerald P Radich, Michael Deininger, Camille N Abboud, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Blood|December 5, 2018
Molecular remission and response patterns in patients with mutant-<i>IDH2</i> acute myeloid leukemia treated with enasidenibEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017Arnel Pallera, Jessica K Altman, Ellin Berman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2023
CML and the WHO: Why?Ellin Berman, Neil P Shah, Michael Deninger, et al.
Blood|October 16, 2025
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical TrialsAndrew Hantel, Yating Wang, Angel Cronin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P Shah, Ravi Bhatia, Jessica K Altman, et al.
Cancer|December 3, 2020
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a studyGautam Borthakur, Yishai Ofran, Martin S Tallman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I TrialNaseema Gangat, Christian Marinaccio, Ronan Swords, et al.
Pageof 37